Seminars in Arthritis and Rheumatism
Volume 40, Issue 2 , Pages 147-163 , October 2010

Tumor Necrosis Factor Inhibitors and Lung Disease: A Paradox of Efficacy and Risk

  • Atul A. Khasnis, MD

      Affiliations

    • Fellow, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH
    • ,
  • Leonard H. Calabrese, DO

      Affiliations

    • Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, RJ Fasenmyer Chair of Clinical Immunology Vice Chairman; Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH
    • Corresponding Author InformationAddress reprint requests to: Leonard H. Calabrese, DO, 9500 Euclid Avenue, A 50, Cleveland, OH 44120

References 

  1. Rychly DJ, DiPiro JT. Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy. 2005;25(9):1181–1192
  2. Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol. 2006;20(4):757–790
  3. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, et al. A metalloproteinase disintegrin that releases tumour necrosis factor-alpha from cells. Nature. 1997;385:729–733
  4. Zhao J, Chen H, Peschon JJ, Shi W, Zhang Y, Frank SJ, et al. Pulmonary Hypoplasia in mice lacking tumor necrosis factor-alpha converting enzyme indicates an indispensable role for cell surface protein shedding during embryonic lung branching morphogenesis. Dev Biol. 2001;232(1):204–218
  5. Trautmann A, Kruger K, Akdis M, Muller-Wening D, Akkaya A, Brocker EB, et al. Apoptosis and loss of adhesion of bronchial epithelial cells in asthma. Int Arch Allergy Immunol. 2005;138(2):142–150
  6. Kampf C, Relova AJ, Sandler S, Roomans GM. Effects of TNF-alpha, IFN-gamma and IL-beta on normal human bronchial epithelial cells. Eur Respir J. 1999;14(1):84–91
  7. Sun M, Fink PJ. A new class of reverse signaling costimulators belongs to the TNF family. J Immunol. 2007;179(7):4307–4312
  8. Vilcek J, Tsujimoto M, Palombella VJ, Kohase M, Le J. Tumor necrosis factor: receptor binding and mitogenic action in fibroblasts. J Cell Physiol Suppl. 1987;(Suppl 5):57–61
  9. Ermert M, Pantazis C, Duncker HR, Grimminger F, Seeger W, Ermert L. In situ localization of TNF alpha/beta (TACE and TNF receptors TNF-R1 and TNF-R2 in control and LPS-treated lung tissue). Cytokine. 2003;22(3-4):89–100
  10. Mazzon E, Cuzzocrea S. Role of TNF-alpha in lung tight junction alteration in mouse model of acute lung inflammation. Respir Res. 2007;8:75
  11. Borron P, McIntosh JC, Korfhagen TR, Whitsett JA, Taylor J, Wright JR. Surfactant-associated protein A inhibits LPS-induced cytokine and nitric oxide production in vivo. Am J Physiol Lung Cell Mol Physiol. 2000;278(4):L840–L847
  12. Miakotina OL, Snyder JM. TNF-alpha inhibits SP-A gene expression in lung epithelial cells via p38 MAPK. Am J Physiol Lung Cell Mol Physiol. 2002;283(2):L418–L427
  13. Ventura JJ, Hübner A, Zhang C, Flavell RA, Shokat KM, Davis RJ. Chemical genetic analysis of the time course of signal transduction by JNK. Mol Cell. 2006;21(5):701–710
  14. Mong PY, Petrulio C, Kaufman HL, Wang Q. Activation of Rho kinase by TNF-alpha is required for JNK activation in human pulmonary microvascular endothelial cells. J Immunol. 2008;180(1):550–558
  15. Wagner EM. TNF-alpha induced bronchial vasoconstriction. Am J Physiol Heart Circ Physiol. 2000;279(3):H946–H951
  16. Lundblad LK, Thompson-Figueroa J, Leclair T, Sullivan MJ, Poynter ME, Irvin G, et al. Tumor necrosis factor-alpha overexpression in lung disease: a single cause behind a complex phenotype. Am J Respir Crit Care Med. 2005;171(12):1363–1370
  17. Chung KF. Cytokines in chronic obstructive pulmonary disease. Curr Drug Targets Inflamm Allergy. 2005;4(6):619–625
  18. Ishii Y, Partridge CA, Del Vecchio PJ, Malik AB. Tumor necrosis factor-alpha-mediated decrease in glutathione increases the sensitivity of pulmonary vascular endothelial cells to H2O2. J Clin Invest. 1992;89(3):794–802
  19. Corda S, Laplace C, Vicaut E, Duranteau J. Rapid reactive oxygen species production by mitochondria in endothelial cells exposed to tumor necrosis factor-alpha is mediated by ceramide. Am J Respir Cell Mol Biol. 2001;24(6):762–768
  20. Van de Vosse E, van Agtmael MA. Targets of anticytokine therapy and the risk of infections in humans and mice. Curr Opin Rheumatol. 2007;19(6):626–635
  21. Bean AG, Roach DR, Briscoe H, France MP, Korner H, Sedgwick JD, et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol. 1999;162(6):3504–3511
  22. Saunders BM, Cooper AM. Restraining mycobacteria: role of granulomas in mycobacterial infections. Immunol Cell Biol. 2000;78(4):334–341
  23. Chensue SW, Warmington K, Ruth J, Lincoln P, Kuo MC, Kunkel SL. Cytokine responses during mycobacterial and schistosomal antigen-induced pulmonary granuloma formation (Production of Th1 and Th2 cytokines and relative contribution of tumor necrosis factor). Am J Pathol. 1994;145(5):1105–1113
  24. Mustafa T, Mogga SJ, Mfinanga SG, Mørkve O, Sviland L. Immunohistochemical analysis of cytokines and apoptosis in tuberculous lymphadenitis. Immunology. 2006;117(4):454–462
  25. Fenhalls G, Stevens L, Bezuidenhout J, Amphlett GE, Duncan K, Bardin P, et al. Distribution of IFN-gamma (IL-4 and TNF-alpha protein and CD8 T cells producing IL-12p40 mRNA in human lung tuberculous granulomas). Immunology. 2002;105(3):325–335
  26. Fenhalls G, Wong A, Bezuidenhout J, van Helden P, Bardin P, Lukey PT. In situ production of gamma interferon, interleukin-4, and tumor necrosis factor alpha mRNA in human lung tuberculous granulomas. Infect Immun. 2000;68(5):2827–2836
  27. Ridley MJ, Heather CJ, Brown I, Willoughby DA. Experimental epithelioid cell granulomas, tubercle formation and immunological competence: an ultrastructural analysis. J Pathol. 1983;141(2):97–112
  28. Baumer I, Zissel G, Schlaak M, Muller-Quernheim J. Th1/Th2 cell distribution in pulmonary sarcoidosis. Am J Respir Cell Mol Biol. 1997;16:171–177
  29. Fehrenbach H, Zissel G, Goldmann T, Tschernig T, Vollmer E, Pabst R, et al. Alveolar macrophages are the main source for tumour necrosis factor-alpha in patients with sarcoidosis. Eur Respir J. 2003;21:421–428
  30. Sharma S, Ghosh B, Sharma SK. Association of TNF polymorphisms with sarcoidosis, its prognosis and tumour necrosis factor (TNF)-alpha levels in Asian Indians. Clin Exp Immunol. 2008;151(2):251–259
  31. Loike JD, Silverstein R, Wright SD, Weitz JI, Huang AJ, Silverstein SC. The role of protected extracellular compartments in interactions between leukocytes, and platelets, and fibrin/fibrinogen matrices. Ann NY Acad Sci. 1992;667:163–172
  32. Heppleston AG, Styles JA. Activity of a macrophage factor in collagen formation by silica. Nature. 1967;214:521–522
  33. Leibovich SJ, Ross R. A macrophage-dependant factor that stimulates the proliferation of fibroblasts in vitro. Am J Pathol. 1976;84:501–513
  34. Goldstein E. Hydrolytic enzymes of alveolar macrophages. Rev Infect Dis. 1983;5(6):1078–1092
  35. Hampson F, Monick M, Peterson MW, Hunninghake GW. Immune mediators increase adherence of T-lymphocytes to human lung fibroblasts. Am J Physiol. 1989;256(2 Pt. 1):C336–C340
  36. Piguet PF, Collart MA, Grau GE, Sappino AP, Vassalli P. Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis. Nature. 1990;344(6263):245–247
  37. Gauldie J, Jordana M, Cox G. Cytokines and pulmonary fibrosis. Thorax. 1993;48(9):931–935
  38. Phan SH, Gharaee-Kermani M, McGarry B, Kunkel SL, Wolber FW. Regulation of rat pulmonary artery endothelial cell transforming growth factor-beta production by IL-1 beta and tumor necrosis factor-alpha. J Immunol. 1992;149(1):103–106
  39. Thornton SC, Robbins JM, Penny R, Breit SN. Fibroblast growth factors in connective tissue disease associated interstitial lung disease. Clin Exp Immunol. 1992;90(3):447–452
  40. Distler JH, Schett G, Gay S, Distler O. The controversial role of tumor necrosis factor alpha in fibrotic diseases. Arthritis Rheum. 2008;58(8):2228–2235
  41. Li YY, Feng YQ, Kadokami T, McTiernan CF, Draviam R, Watkins SC, et al. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. Proc Natl Acad Sci USA. 2000;97(23):12746–12751
  42. Ouellet S, Yang H, Aubin RA, Hawley RG, Wenckebach GF, Lemaire I. Bidirectional modulation of TNF-alpha production by alveolar macrophages in asbestos-induced pulmonary fibrosis. J Leukoc Biol. 1993;53(3):279–286
  43. Paulsson Y, Austgulen R, Hofsli E, Heldin CH, Westermark B, Nissen-Meyer J. Tumor necrosis factor-induced expression of platelet-derived growth factor A-chain messenger RNA in fibroblasts. Exp Cell Res. 1989;180:490–496
  44. Takahashi S, Dunn MA, Seifter S. Liver collagenase in murine schistosomiasis. Gastroenterology. 1980;78(6):1425–1431
  45. Schiltz JR, Olds GR, Kresina TF, Mahmoud AA. Effect of chemotherapy on hepatic collagen and glycosaminoglycan metabolism in Schistosoma mansoni-infected mice. Trans R Soc Trop Med Hyg. 1988;82(6):868–873
  46. Grimaud JA, Boros DL, Takiya C, Mathew RC, Emonard H. Collagen isotypes, and fibronectin in granulomas of the liver and intestines of Schistosoma mansoni-infected mice. Am J Trop Med Hyg. 1987;37(2):335–344
  47. Gosset P, Tsicopoulos A, Wallaert B, Vannimenus C, Joseph M, Tonnel AB, et al. Increased secretion of tumor necrosis factor alpha and interleukin-6 by alveolar macrophages consecutive to the development of the late asthmatic reaction. J Allergy Clin Immunol. 1991;88(4):561–571
  48. Ohkawara Y, Yamauchi K, Tanno Y, Tamura G, Ohtani H, Nagura H, et al. Human lung mast cells and pulmonary macrophages produce tumor necrosis factor-α in sensitized lung tissue after IgE receptor triggering. Am J Respir Cell Mol Biol. 1992;7:385–392
  49. Deveci F, Muz MH, Ilhan N, Kirkil G, Turgut T, Akpolat N. Evaluation of the anti-inflammatory effect of infliximab in a mouse model of acute asthma. Respirology. 2008;13(4):488–497
  50. Khalil-Saadeh C, Brown DM, Chumney-Malacara JC, Crow J. Infliximab therapy for rheumatoid arthritis (RA) induced significant control of asthma in patients with both RA and asthma or asthma/COPD in addition to improving RA status. J. Allergy Clin Immunol. 2002;109(Suppl 1):s243
  51. Berry MA, Hargadon B, Shelley M, Parker D, Shaw DE, Green RH, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med. 2006;354(7):697–708
  52. Erin EM, Leaker BR, Nicholson GC, Tan AJ, Green LM, Neighbour H, et al. The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit Care Med. 2006;174(7):753–762
  53. Wenzel SE, Barnes PJ, Bleecker ER, Bousquet J, Busse W, Dahlén SE, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med. 2009;179(7):549–558
  54. Erzurum SC. Inhibition of tumor necrosis factor alpha for refractory asthma. N Engl J Med. 2006;354(7):754–758
  55. Zhang C, Cai S, Chen P, Chen JB, Wu J, Wu SJ, et al. Inhibition of tumor necrosis factor-alpha reduces alveolar septal cell apoptosis in passive smoking rats. Chin Med J (Engl). 2008;121(7):597–601
  56. van der Vaart H, Koëter GH, Postma DS, Kauffman HF, ten Hacken NH. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172(4):465–469
  57. Rennard SI, Fogarty C, Kelsen S, Long W, Ramsdell J, Allison J, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(9):926–934
  58. Russo C, D'Angelo F, Polosa R. Study of infliximab treatment in smokers with COPD: what next?. Am J Respir Crit Care Med. 2005;172(12):1607–1608
  59. Barnes P. Unexpected failure of anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175:866–867
  60. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2001;18(1):70–74
  61. Yee AM, Pochapin MB. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy. Ann Intern Med. 2001;135(1):27–31
  62. Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest. 2005;127(3):1064–1071
  63. Ramos-Casals M, Brito-Zerón P, Muñoz S, Soto MJ BIOGEAS STUDY Group. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore). 2008;87(6):345–364
  64. Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, du Bois R, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174(7):795–802
  65. Rossman MD, Newman LS, Baughman RP, Teirstein A, Weinberger SE, Miller W, et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2006;23(3):201–208
  66. Callejas-Rubio JL, Ortego-Centeno N, Lopez-Perez L, Benticuaga MN. Treatment of therapy-resistant sarcoidosis with adalimumab. Clin Rheumatol. 2006;25(4):596–597
  67. Khanna D, Liebling MR, Louie JS. Etanercept ameliorates sarcoidosis arthritis and skin disease. J Rheumatol. 2003;30(8):1864–1867
  68. Utz JP, Limper AH, Kalra S, Specks U, Scott JP, Vuk-Pavlovic Z, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest. 2003;124(1):177–185
  69. Piguet PF, Ribaux C, Karpuz V, Grau GE, Kapanci Y. Expression and localization of tumor necrosis factor-alpha and its mRNA in idiopathic pulmonary fibrosis. Am J Pathol. 1993;143(3):651–655
  70. Vassallo R, Matteson E, Thomas CF. Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition. Chest. 2002;122(3):1093–1096
  71. Bargagli E, Galeazzi M, Rottoli P. Infliximab treatment in a patient with rheumatoid arthritis and pulmonary fibrosis. Eur Respir J 708;24(4):708.
  72. Antoniou KM, Mamoulaki M, Malagari K, Kritikos HD, Bouros D, Siafakas NM, et al. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin Exp Rheumatol. 2007;25(1):23–28
  73. Braun-Moscovici Y, Markovits D, Rozin A, Toledano K, Nahir AM, Balbir-Gurman A. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results. Isr Med Assoc J. 2008;10(4):277–281
  74. Raghu G, Brown KK, Costabel U, Cottin V, du Bois RM, Lasky JA, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med. 2008;178(9):948–955
  75. Ramos-Casals M, Brito-Zerón P, Muñoz S, Soria N, Galiana D, Bertolaccini L, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007;86(4):242–251
  76. Toussirot E, Pertuiset E, Kantelip B, Wendling D. Sarcoidosis during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases. Clin Exp Rheumatol. 2008;26(3):471–475
  77. Verschueren K, Van Essche E, Verschueren P, Taelman V, Westhovens R. Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients. Clin Rheumatol. 2007;26(11):1969–1971
  78. O'Shea FD, Marras TK, Inman RD. Pulmonary sarcoidosis developing during infliximab therapy. Arthritis Rheum. 2006;55(6):978–981
  79. Kudrin A, Chilvers ER, Ginawi A, Hazleman BL, Griffiths MH, Thiru S, et al. Sarcoid-like granulomatous disease following etanercept treatment for RA. J Rheumatol. 2007;34(3):648–649
  80. Louie GH, Chitkara P, Ward MM. Relapse of sarcoidosis upon treatment with etanercept. Ann Rheum Dis. 2008;67(6):896–898
  81. Ishiguro T, Takayanagi N, Kurashima K, Matsushita A, Harasawa K, Yoneda K, et al. Development of sarcoidosis during etanercept therapy. Intern Med. 2008;47(11):1021–1025
  82. González-López MA, Blanco R, González-Vela MC, Fernández-Llaca H, Rodríguez-Valverde V. Development of sarcoidosis during etanercept therapy. Arthritis Rheum. 2006;55(5):817–820
  83. Farah RE, Shay MD. Pulmonary sarcoidosis associated with etanercept therapy. Pharmacotherapy. 2007;27(10):1446–1448
  84. Phillips K, Weinblatt M. Granulomatous lung disease occurring during etanercept treatment. Arthritis Rheum. 2005;53(4):618–620
  85. Almodóvar R, Izquierdo M, Zarco P, Javier Quirós F, Mazzucchelli R, Steen B. Pulmonary sarcoidosis in a patient with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol. 2007;25(1):99–101
  86. Sweiss NJ, Baughman RP. Tumor necrosis factor inhibition in the treatment of refractory sarcoidosis: slaying the dragon?. J Rheumatol. 2007;34(11):2129–2131
  87. Casey MB, Tazelaar HD, Myers JL, Hunninghake GW, Kakar S, Kalra SX, et al. Noninfectious lung pathology in patients with Crohn's disease. Am J Surg Pathol. 2003;27(2):213–219
  88. Fallahi S, Collins RD, Miller RK, Halla JT. Coexistence of rheumatoid arthritis and sarcoidosis: difficulties encountered in the differential diagnosis of common manifestations. J Rheumatol. 1984;11(4):526–529
  89. Rozin A, Yigla M, Guralnik L, Keidar Z, Vlodavsky E, Rozenbaum M, et al. Rheumatoid lung nodulosis and osteopathy associated with leflunomide therapy. Clin Rheumatol. 2006;25(3):384–388
  90. Inoue K, Takano H, Yanagisawa R, Yoshikawa T. Effects of tumor necrosis factor-alpha inhibitors on lung lesions with rheumatoid arthritis. Chest. 2003;124(1):413–414
  91. Cuchacovich R, Espinoza CG, Virk Z, Espinoza LR. Biologic therapy (TNF-alpha antagonists)-induced psoriasis: a cytokine imbalance between TNF-alpha and IFN-alpha?. J Clin Rheumatol. 2008;14(6):353–356
  92. Chatterjee S. Severe interstitial pneumonitis associated with infliximab therapy. Scand J Rheumatol. 2004;33(4):276–277
  93. Ostor AJ, Crisp AJ, Somerville MF, Scott DG. Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab. BMJ 1266;329(7477):1266.
  94. Tengstrand B, Ernestam S, Engvall IL, Rydvald Y, Hafström I. TNF blockade in rheumatoid arthritis can cause severe fibrosing alveolitis (Six case reports). Lakartidningen. 2005;102(49):3788–37903793
  95. Lindsay K, Melsom R, Jacob BK, Mestry N. Acute progression of interstitial lung disease: a complication of etanercept particularly in the presence of rheumatoid lung and methotrexate treatment. Rheumatology (Oxford). 2006;45(8):1048–1049
  96. Tournadre A, Ledoux-Eberst J, Poujol D, Dubost JJ, Ristori JM, Soubrier M. Exacerbation of interstitial lung disease during etanercept therapy: two cases. Joint Bone Spine. 2008;75(2):215–218
  97. Hagiwara K, Sato T, Takagi-Kobayashi S, Hasegawa S, Shigihara N, Akiyama O. Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis. J Rheumatol. 2007;34(5):1151–1154
  98. Huggett MT, Armstrong R. Adalimumab-associated pulmonary fibrosis. Rheumatology (Oxford). 2006;45(10):1312–1313
  99. Schoe A, van der Laan-Baalbergen NE, Huizinga TW, Breedveld FC, van Laar JM. Pulmonary fibrosis in a patient with rheumatoid arthritis treated with adalimumab. Arthritis Rheum. 2006;55(1):157–159
  100. Villeneuve E, St-Pierre A, Haraoui B. Interstitial pneumonitis associated with infliximab therapy. J Rheumatol. 2006;33(6):1189–1193
  101. Mori S, Imamura F, Kiyofuji C, Sugimoto M. Development of interstitial pneumonia in a rheumatoid arthritis patient treated with infliximab, an anti-tumor necrosis factor alpha-neutralizing antibody. Mod Rheumatol. 2006;16(4):251–255
  102. Weatherhead M, Masson S, Bourke SJ, Gunn MC, Burns GP. Interstitial pneumonitis after infliximab therapy for Crohn's disease. Inflamm Bowel Dis. 2006;12(5):427–428
  103. Quintos-Macasa AM, Quinet R. Enbrel-induced interstitial lung disease. South Med J. 2006;99(7):783–784
  104. Allanore Y, Devos-François G, Caramella C, Boumier P, Jounieaux V, Kahan A. Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab. Ann Rheum Dis. 2006;65(6):834–835
  105. Cairns AP, Taggart AJ. Anti-tumour necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland. Ulster Med J. 2002;71:101–105
  106. Wolfe F, Caplan L, Michaud K. Rheumatoid arthritis treatment and the risk of severe interstitial lung disease. Scand J Rheumatol. 2007;36(3):172–178
  107. http://www.bjdonline.org/default.aspx?contId=944. BSRBR Newsletter August 2004 by BSRBR—published in BSR, 2005-08-31.
  108. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial (ATTRACT Study Group). Lancet. 1999;354(9194):1932–1939
  109. Garcia-Vicuña R, Ortiz AM, Carmona L, Ibáñez M, Castrejón I, Laffón A. Inflammatory Interstitial Lung Disease in rheumatoid arthritis patients treated with biologic treatment (Incidence and mortality rates compared with patients non receiving biologics). Ann Rheum Dis. 2005;64(Suppl III):470
  110. Ryan JG, Murphy E, Barry M. Biologic therapy: a countrywide survey of anti-TNF use and associated complications. Ann Rheum Dis. 2006;65(Suppl II):499
  111. Hyrich K, Symmons D, Watson K, Silman A. BSRBR Control Centre Consortium; British Society for Rheumatology Biologics Register (Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register). Ann Rheum Dis. 2006;65(7):895–898
  112. Pincus T, Sokka T. Uniform databases in early arthritis: specific measures to complement classification criteria and indices of clinical change. Clin Exp Rheumatol. 2003;21(5 Suppl 31):S79–S88
  113. Kramer N, Chuzhin Y, Kaufman LD, Ritter JM, Rosenstein ED. Methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. Arthritis Rheum. 2002;47(6):670–671
  114. Courtney PA, Alderdice J, Whitehead EM. Comment on methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. Arthritis Rheum. 2003;49(4):617;author reply, 617-8
  115. Suissa S, Hudson M, Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum. 2006;54(5):1435–1439
  116. Wright SA, Brown K, McCracken D, Taggart AJ. The use of biologic agents for severe inflammatory arthritis in Northern Ireland (EULAR). [FRI0017] Abstract Archive http://www.abstracts2view.com/eular/sessionindex.php2004;
  117. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59(6):762–784
  118. Ledingham J, Deighton C British Society for Rheumatology Standards, Guidelines and Audit Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNF alpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford). 2005;44(2):157–163
  119. Furst DE, Keystone EC, Kirkham B, Fleischmann R, Mease P, Breedveld FC, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis. 2008;67(Suppl III):iii2–iii25
  120. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment (International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS)). Am J Respir Crit Care Med. 2000;161(2 Pt. 1):646–664
  121. http://www.nice.org.uk/nicemedia/pdf/TA130guidance.pdf.
  122. http://www.rxabbott.com/pdf/humira.pdf.
  123. http://www.remicade.com/remicade/assets/HCP_PPI.pdf.
  124. http://www.enbrel.com/pdf/enbrel_pi.pdf.
  125. Leombruno JP, Einarson TR, Keystone EC. Incidence and incidence density of death in controlled clinical trials of anti-TNF drugs in rheumatoid arthritis. Ann Rheum Dis. 2005;64(Suppl III):464
  126. Askling J, Dixon W. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol. 2008;20(2):138–144
  127. Cambien B, Bergmeier W, Saffaripour S, Mitchell HA, Wagner DD. Antithrombotic activity of TNF-alpha. J Clin Invest. 2003;112(10):1589–1596
  128. Ferraro-Peyret C, Coury F, Tebib JG, Bienvenu J, Fabien N. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther. 2004;6(6):R535–R543
  129. Panagi S, Palka W, Korelitz BI, Taskin M, Lessnau KD. Diffuse alveolar hemorrhage after infliximab treatment of Crohn's disease. Inflamm Bowel Dis. 2004;10(3):274–277
  130. Musiał J, Undas A, Celińska-Lowenhoff M. Polymyositis associated with infliximab treatment for rheumatoid arthritis. Rheumatology (Oxford). 2003;42(12):1566–1568

 The authors have no conflicts of interest to disclose.

PII: S0049-0172(09)00115-2

doi: 10.1016/j.semarthrit.2009.09.001

Seminars in Arthritis and Rheumatism
Volume 40, Issue 2 , Pages 147-163 , October 2010

Article Tools

* Image Usage & Resolution